Targeting SR-BI for Cancer Diagnostics, Imaging and Therapy

Area of Science:

• Biochemistry
• Oncology
• Nanomedicine

Background:

• Scavenger receptor class B type I (SR-BI) mediates cholesteryl ester transfer between high-density lipoprotein and the liver.
• SR-BI is implicated in cholesterol metabolism within cancer cells and is overexpressed in various tumors, including breast and prostate cancers.

Approach:

• This review highlights the use of SR-BI as a biomarker and therapeutic target in oncology.
• Exploration of high-density lipoprotein (HDL) nanomimetic platforms for targeted drug delivery and diagnostics.

Key Points:

• Overexpression of SR-BI in tumors presents an opportunity for targeted cancer therapies.
• HDL-mimetic platforms leverage SR-BI upregulation for enhanced drug delivery and imaging.
• SR-BI targeted agents show promise for direct cytosolic delivery of therapeutics.

Conclusions:

• SR-BI is a promising target for developing novel cancer diagnostics and therapeutics.
• HDL-mimetic nanoplatforms offer a viable strategy for SR-BI-targeted cancer treatment.
• Future research directions focus on advancing SR-BI-targeted agents for clinical applications.